Biotech Values

[ghmm]

Question Stroke Drugs in Trials -

For those companies with treatments beyond the 3-4 hour range why wouldn't they go after those outside the TPA treatment window? Is there anything approved for beyond this range?

The other concern I have (I follow Neurobiological a bit) is those companies with treatments beyond 3 hours is it more likely they get those patience in their trials and thus have a harder chance to get efficacy (even over placebo) if in fact the treatment window is not quite as big as they think it is for their drug?